Cerevance successfully completes Phase 1 clinical trial of CVN424
Category: #health  By Pankaj Singh  Date: 2019-05-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cerevance successfully completes Phase 1 clinical trial of CVN424

Clinical stage biopharmaceutical company Cerevance has reportedly completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, oral drug in development for treating Parkinson’s disease. The clinical study effectively attained its chief endpoint of safety in healthy volunteers.

The study reportedly comprised 64 healthy volunteers who were given either single dose or 7 daily doses of CVN424, extending from 1 mg to 225 mg, or placebo. There were no adverse events or clinically noteworthy changes in vital signs, laboratory values or ECG values. The drug was quickly absorbed orally and held a half-life that would support once-daily dosing, cited sources.

David H. Margolin, MD, Ph.D., Cerevance’s Senior VP for Clinical and Translational Medicine, said that CVN424’s brilliant safety profile helps authenticate the company’s approach to drug discovery and CNS target selection. The drug acts via a target that is selectively expressed by neurons significant in managing movement and was designed to attain excellent CNS penetration with nominal effects on other organs, Margolin added.

CVN424 targets novel, non-dopaminergic target protein, particularly existent in dopamine receptor D2-expressing medium spiny neurons within the basal ganglia’s indirect pathway. The drug controls the indirect pathway dependent on D2, but not the direct pathway dependent on D1. This selective aiming is developed to produce positive therapeutic effects of present treatments while preventing side effects like dyskinesia linked with dopaminergic therapies, cited sources familiar with the new therapy.

Brad Margus, CEO of Cerevance, said in a statement that the company is satisfied with the outcomes of the Phase 1 trial results for CVN424 and are keen on advancing to Phase 2. The company’s NETSseq technology platform makes use of human post-mortem brain tissue to detect targets that are selectively expressed in certain cell types and circuits or altered in disease states, enabling discovery of new treatments for neurodegenerative diseases, Margus added. 

On the basis of the positive Phase 1 outcomes, a Phase 2 study to exhibit the clinical advantages of CVN424 will be commenced later this year, reported sources.
Source Credits: https://www.businesswire.com/news/home/20190430005080/en/Cerevance-Achieves-Key-Endpoints-Phase-1-Clinical

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Dressbarn confirms 53 stores to close in August as wind down nears
Dressbarn confirms 53 stores to close in August as wind down nears
By Pankaj Singh

Ascena shares have been down by more than 75% this year and are trading at below $1 Ascena Retail Group, an American retailer for women’s clothing, recently announced that it is going to shut down 53 locations of Dressbarn by the end of August...

Japan introduces working group to examine impact of Facebook’s Libra
Japan introduces working group to examine impact of Facebook’s Libra
By Pankaj Singh

Japan is looking to garner greater support due to the wide range of policies which can be affected by digital currencies. Japanese authorities have reportedly established a working group to discuss the impact Libra digital coin proposed by Facebook ...

Ligand Pharma announces positive results from trial of CE-Iohexol
Ligand Pharma announces positive results from trial of CE-Iohexol
By Pankaj Singh

Ligand Pharmaceuticals, a US-based biopharmaceutical company recently announced positive top line results from clinical trial of its internal CE (Captisol-enabled) Iohexol program. The study attained primary endpoint indicating pharmacokinetic b...